It is time to re-engage with 'true innovators' in pharma industry

US govt likely to be supportive of biomedical research

The US Presidential Election has finally come and gone. It is time for investors to re-engage with the pharmaceutical and biotechnology sector.

For more than a year the sector has been under pressure as investors fret over the prospect of further healthcare system reform in the US, particularly government intervention in drug pricing in the wake of intense scrutiny on the practices of a handful of executives, who have exploited the structure of the notoriously complex US healthcare system.  While the fractious, obstructive nature of Washington politics is well known, we expect to see bipartisan efforts to close down opportunities for 'price gouging' behaviour on older generic medicines. How could a new president impact the US...